February 2013

Hepatitis C treatment is a rapidly changing field. This workshop, presented by Professor Robert Batey from the University of Sydney and the Royal Prince Alfred Hospital, will provide an update on hepatitis C patient assessment and monitoring among professionals working in primary care.

This workshop also aims to increase awareness of treatment options and aid decision-making around treatment suitability. Part one of the workshop will provide information on advances in patient assessment including FibroScan and genetic testing. The use and side effects of the newly approved direct-acting antivirals (DAA) telaprevir and boceprevir will be reviewed and future interferon-free antiviral regimes will be discussed. The second part of the workshop will be case-based, enabling practitioners to identify patients with advanced liver disease who need more urgent treatment.  Workshop participants will be invited to participate in this interactive keypad session.

Location: Medicines in Addiction Conference 2013, Sydney, Australia

Presenter: Professor Robert Batey, Professor of Addiction Medicine, University of Sydney

When: Friday, 15 March 2013

Register online at https://www.etouches.com/ereg/index.php?eventid=48272&

Contact: Sonja Hill, ASHM – [email protected]